4,222 nuclear genes regulated. One 16-amino-acid tripeptide. Encoded not in the nucleus — but in the very genome of your mitochondria.
When Changhan David Lee's team at the University of Southern California published their 2015 findings in Cell Metabolism, the response from the research community was stunned silence followed by a scramble to replicate. A peptide had been hiding inside a region of mitochondrial DNA that scientists had classified for decades as non-coding structural RNA.
Contents
What Is MOTS-c Peptide?
MOTS-c — short for Mitochondrial Open Reading Frame of the 12S rRNA-c — is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR and a molecular weight of approximately 2,174 Da. That sequence is encoded in the mitochondrial genome: specifically from a previously overlooked open reading frame nested within the 12S ribosomal RNA gene of mitochondrial DNA (mtDNA).
MOTS-c belongs to the emerging class of molecules called mitokines — signaling peptides of mitochondrial origin that communicate metabolic status to other organelles, other cells, and potentially to distant tissues via circulation. Its classification as an exercise mimetic comes from its ability to activate AMP-activated protein kinase (AMPK) in skeletal muscle, mirroring one of the central molecular events triggered by endurance training.
Genetic Origin: Hidden in Plain Sight

The human mitochondrial genome is 16,569 base pairs of circular, double-stranded DNA. For decades, the 12S rRNA gene was treated as purely structural — a scaffold for ribosomal assembly inside the mitochondrial matrix. Lee et al. identified the ORF encoding MOTS-c using bioinformatics, ribosomal profiling, and mass spectrometry confirmation of the translated peptide in human cells.
The sequence is highly conserved across mammals. Against the background mutation rate of mitochondrial DNA (which evolves roughly 10 to 17 times faster than nuclear DNA), a sequence that remains stable across rodents, primates, and humans over millions of years is not there by accident. Conservation at that level typically means selection pressure — and selection pressure means function.
Mechanism of Action: The Folate-AMPK Axis
AMPK (AMP-activated protein kinase) is the master regulator of cellular energy homeostasis. When ATP is depleted and AMP rises — during fasting, exercise, hypoxia, or caloric restriction — AMPK shifts the cell from energy-consuming to energy-producing mode.
The Folate Cycle Connection
Most AMPK activators work by directly modulating the AMP/ATP ratio. MOTS-c takes a different route — and this mechanistic distinction is why it attracted so much interest. After leaving the mitochondria (likely during mitochondrial stress), MOTS-c translocates to the nucleus, where it inhibits the folate cycle — specifically methylenetetrahydrofolate reductase (MTHFR). When the folate cycle backs up, upstream intermediates accumulate, including AICAR and its phosphorylated form ZMP. ZMP is a structural analog of AMP. When intracellular ZMP levels rise, AMPK reads it as a drop in energy status and activates accordingly.
MOTS-c triggers AMPK without directly touching ATP levels — through a metabolite-mediated mechanism that is, as Lee et al. described it, “more physiological” than direct AMPK agonists.
The Exercise Mimetic Question
An exercise mimetic, rigorously defined, is a compound that reproduces specific molecular signatures of physical exercise at the cellular level. AMPK activation in skeletal muscle, increased fatty acid oxidation, glucose uptake independent of insulin, PGC-1α induction — these are the molecular targets.
MOTS-c's comparison against the molecular events of endurance exercise shows significant overlap: AMPK activation and insulin-independent glucose uptake are well-documented for both exercise and MOTS-c. Cardiovascular adaptation, VO2max improvement, structural changes to muscle fiber type — none of these are in the MOTS-c literature. The peptide recapitulates specific metabolic pathways, not the full program.
The Exerkine Hypothesis
Research groups studying “exerkines” — circulating peptides released during physical activity — have found evidence that MOTS-c plasma levels rise transiently after acute exercise in rodent models. If confirmed in humans, this would reframe MOTS-c as an endogenous mediator that the body uses during exercise — one that declines with age and may become a limiting factor in the metabolic response to training in older populations.
Preclinical Data: What the Studies Show
Lee et al., 2015 — Cell Metabolism (PMID: 25738455)
The foundational paper. In a high-fat diet (HFD) model, daily intraperitoneal injections of MOTS-c at 15 mg/kg were administered for 4 to 8 weeks. Animals receiving MOTS-c showed reduced body weight gain, improved glucose tolerance, improved insulin tolerance, and reduced hepatic lipid accumulation versus vehicle controls. Skeletal muscle AMPK phosphorylation was elevated. Mechanistic validation using AMPK inhibitors and siRNA confirmed AMPK dependency. Age-related decline: plasma MOTS-c concentrations in aged mice (20-24 months) were significantly lower than in young adults (3-4 months).
Kim et al., 2021 — Nature Communications
Extended the MOTS-c-aging connection to human data. MOTS-c levels declined progressively with age in the general population, but exceptionally long-lived individuals (centenarians and semi-supercentenarians) showed higher-than-expected MOTS-c concentrations relative to their age-matched peers. Correlations found between MOTS-c levels and metabolic markers including fasting glucose and triglycerides.
MOTS-c and the Biology of Aging
MOTS-c plasma levels follow a pattern consistent with several other longevity-associated molecules: robust in early adulthood, declining progressively through middle age, substantially reduced in older populations. The inference — that restoring MOTS-c to youthful concentrations might delay aspects of metabolic aging — is biologically plausible and drives significant research interest. It has not been demonstrated in controlled human trials.
Aging biology has moved toward viewing mitochondrial dysfunction as a driver of systemic aging. Failing mitochondria produce fewer and altered signaling molecules that the rest of the body depends on for metabolic coordination. MOTS-c represents one of the cleaner mechanistic stories in this space — a defined sequence, a defined target (the folate-AMPK axis), and a coherent physiological narrative.
The Mitokine Family: Context Matters
Humanin
Humanin was the first identified mitochondrially encoded peptide, discovered in 2001. It is 21 amino acids long and acts primarily via cell surface receptors. Humanin has neuroprotective, cytoprotective, and insulin-sensitizing properties. Like MOTS-c, its plasma levels decline with age. Mechanistic difference: humanin largely signals through plasma membrane receptors (acting like a cytokine), while MOTS-c enters the nucleus and acts through metabolic pathway modulation.
SHLP Peptides (1-6)
The Small Humanin-Like Peptides (SHLP 1 through 6) were described by Cobb et al. in 2016. SHLP2 and SHLP3 have shown particular activity in metabolic and longevity models. The full characterization of SHLPs remains a work in progress.
Frequently Asked Questions
Is MOTS-c the only peptide encoded by mitochondrial DNA?
No. Humanin was the first identified, discovered in 2001 from the 16S rRNA gene. The SHLP family (SHLP1-6) was subsequently identified in the same genomic region. MOTS-c is distinctive in originating from the 12S rRNA gene and in its specific mechanism through the nuclear folate cycle. The mitochondrial genome likely encodes additional uncharacterized peptides — the field calls this the mitochondrial peptidome.
How does MOTS-c differ mechanistically from other AMPK activators like AICAR or metformin?
AICAR activates AMPK directly by being converted to ZMP (an AMP analog). Metformin acts primarily by inhibiting Complex I of the mitochondrial electron transport chain, raising the AMP/ATP ratio. MOTS-c inhibits the folate cycle in the nucleus, causing AICAR and ZMP to accumulate as metabolic byproducts — those then activate AMPK. The cascade is indirect and physiologically grounded in a mechanism the body appears to use endogenously.
Are there human clinical trials on MOTS-c peptide?
As of early 2026, no published controlled clinical trials on exogenous MOTS-c administration in humans exist. Human data consists of epidemiological studies measuring endogenous plasma MOTS-c levels. The mechanistic basis for human trials is scientifically plausible, but the gap between preclinical rodent data and clinical translation remains to be bridged.
Does exercise increase endogenous MOTS-c levels?
Animal data suggests yes — acute aerobic exercise in rodents produces transient increases in circulating MOTS-c, supporting the hypothesis that MOTS-c is an exerkine. The data in humans is limited and inconsistent across studies. The exerkine framing is compelling but requires substantially more data before conclusions can be drawn.
What is the relationship between MOTS-c and insulin sensitivity?
In murine models of diet-induced insulin resistance, exogenous MOTS-c improved insulin tolerance and increased skeletal muscle GLUT4 translocation in an AMPK-dependent manner. This insulin-independent pathway is mechanistically similar to exercise-induced glucose uptake. Whether this translates to clinically meaningful insulin sensitization in humans has not been tested in controlled trials.
Available from UNIK LAB
MOTS-c 10mg€39
Research-grade MOTS-c 10mg · HPLC verified ≥98% · COA included · 48h EU/UK dispatch
